U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
MIRAMAR, Fla., Aug. 03, 2022 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company”) NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, was granted U.S. Patent 11,401,324 which contains claims for immunotherapeutic compounds comprised of a single-chain chimeric polypeptide with two target-binding domains on a scaffold made of an extracellular domain of human tissue factor.
This patent provides intellectual property protection for the lead drug candidate, HCW9302, a single-chain, IL-2-based fusion protein designed to activate and expand regulatory T ("Treg") cells to suppress the activity of inflammasome-bearing cells and the inflammatory factors which they secrete. Preclinical studies in mouse models have demonstrated the ability of HCW9302 to activate Treg cells and reduce inflammation-related disease pathologies, supporting the potential of HCW9302 to treat a wide variety of autoimmune and proinflammatory diseases. HCW9302 is currently completing IND-enabling activities for an IND application for a clinical trial in an autoimmune disorder.
HCW Biologics has created an extensive patent portfolio with multiple families of patent applications that are directed to its internally developed TOBI™ discovery platform technology for creation of novel single-chain and multi-chain chimeric polypeptides as well as methods of use of these polypeptides alone and in combination.
Hing C. Wong, Ph.D., Founder and CEO of HCW Biologics, expressed his excitement upon reaching this milestone by stating, “We are thrilled to announce the issuance of a patent that has allowed such broad claims. The issuance of our first patent marks an important step in the evolution of our patent portfolio. This news, along with our progress in the prosecution of our other patent applications,reinforces our belief that our novel single-chain and multi-chain immunotherapeutics, as well as the proprietary approach used to create them with our TOBI™ discovery platform, are novel, valuable assets. We are pleased that this patent has been granted by the U.S. Patent and Trademark Office, providing vital recognition and protection of the intellectual property on which we based one of our lead product candidates, HCW9302.”
HCW Biologics is represented by the leading global intellectual property law firm, Fish & Richardson P.C. “From the beginning, we have worked with HCW Biologics to build a portfolio of foundational patents which will protect the Company’s technology, inventions and improvements that are commercially important to the foundation of its business,” observed Tiffany A. Reiter, Ph.D., Principal in the Boston office of Fish & Richardson P.C.
About HCW Biologics:
Forward Looking Statements: